前立腺癌Stage D2に対するLH-RH agonist単独療法とFlutamide併用療法の比較

Abstract

前立腺癌stage D2に対する, LH-RH agonist単独療法とflutamide併用combined androgen blockade(CAB)療法の治療効果を比較検討した.治療開始3ヵ月後の血清PSA値は差がなかったが, progression-free survival rateは有意にCAB療法が高い傾向が見られた.特に, 低分化度症例で有意差が見られた.EOD 2以上の症例では差を認めなかった

We compared the clinical efficacy of treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist alone to combined androgen blockade (CAB) with a LH-RH agonist and fiutamide. A total of 66 stage D2 prostate cancer patients were enrolled from Nov. 1992 to Mar. 1996 (n = 30: LH-RH agonist alone, n = 36 CAB). Serum PSA levels after 3 months of treatment and progression-free survival rates (Kaplan-Meier curves) were compared. Results were statistically evaluated by Wilcoxon's text. There were no differences in PSA levels between LH-RH agonist alone and CAB. Progression-free survival rates were longer in the patients treated CAB compared to LH-RH agonist alone (P = 0.041). Furthermore, in patients with poorly differentiated prostate cancers, longer survival rates were also observed with CAB (P = 0.030). However, there were no differences in high EOD (> or = 2) patients between the two treatments (P = 0.652).